Health
Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC
Headline as filed by Medical Xpress.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| Medical Xpress | Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC |
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small ce |
0m | medicalxpress.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.